The Oncology Journal Club Episode 12

Pinterest LinkedIn Tumblr +

In this week’s episode of The Oncology Journal Club, our host Eva Segelov talks us through Proton Beam Therapy. Craig Underhill reviews papers that bring new standards of care in lung cancer from the recent World Lung Cancer Conference. And its Hans Prenen’s turn for a guest interview this week…

Eva’s engaging talk on proton beam therapy will bring you right up to date on this and Craig gives us comprehensive reviews of practice changing papers from the WLCC, of course with a few jokes squeezed in amidst the analysis.

Hans Prenen chats about nanotech with our guest interviewee this week – Associate Professor Giovanni Maglia who is an expert in Electrophysiology and Single-molecule Nanopore Technology at the University of Gronginen in The Netherlands. Han’s Quick Bites includes an update on the cytosponge and a thought provoking study on industry payments to Australian medical oncologists and haematologists.

With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

Today’s episode is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource. Please let us know what you think!

This Week’s Papers:

Main Papers:

  1. Lin, Steven H., et al.  Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology 38, no. 14 (May 10, 2020) 1569-1579. DOI: 10.1200/JCO.19.02503. Access online here.
  2. Simone II, Charles B. First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer. Journal of Clinical Oncology. Published online July 24, 2020. DOI: 10.1200/JCO.20.01405. Access online here.

Papers from the IASLC-WCLC

  1. Abstract 1:  Zhang, Li et al. ORIENT-11: sintilimab + pemetrexed + platinum as first-line therapy for locally advanced or metastatic non-squamous NSCLC. IASLC-WCLC 2020 Presidential Symposium. August 8, 2020. Access online here.
  2. Abstract 2: Abstract 3: Horn, L., et al. Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients: eXalt3. IASLC-WCLC 2020 Presidential Symposium. August 8, 2020. Access online here.
  3. Baas, Paul, et al. First-line nivolumab + ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743. IASLC-WCLC 2020 Presidential Symposium. August 8, 2020. Access online here.

Guest Interview:

In today’s episode we have a special interview on Nanotechnology with Hans Prenen and Giovanni Maglia.

Quick Bites:

  1. Salama, AKS., et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H [published online ahead of print, 2020 Aug 6]. J Clin Oncol. 2020;JCO2000762. doi:10.1200/JCO.20.00762. Access online here.
  2. Rovers, KP., et al. Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases [published online ahead of print, 2020 Jul 16]. JAMA Oncol. 2020;6(8):e202701. doi:10.1001/jamaoncol.2020.2701. Access online here.
  3. Fitzgerald, RC., et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396(10247):333-344. doi:10.1016/S0140-6736(20)31099-0. Access online here.
  4. Pokorny, AM., et al. Industry payments to Australian medical oncologists and clinical haematologists: a cross-sectional analysis of publicly-available disclosures [published online ahead of print, 2020 Aug 3]. Intern Med J. 2020;10.1111/imj.15005. doi:10.1111/imj.15005. Access online here.

PBS Update:

LYNPARZA is now PBS listed for both somatic BRCAm and germline BRCAm in 2nd-line maintenance of platinum-sensitive relapsed high-grade ovarian cancer (≥2 prior courses of platinum-based regimens).  More information here.

Investor Update:

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer. Access online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.



Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Giovanni Maglia

Professor Giovanni Maglia studied chemistry at the University of Bologna, Italy received his PhD in chemical biology at the University of Birmingham (2004), UK and continued his studies in biophysics at the Universities of Leuven, BE and Oxford, UK. Giovanni’s post-doctoral work crucially contributed to the commercialisation of DNA sequencing with nanopore. As an independent researcher, Giovanni’s group has pioneered the use of biological nanopores as molecular machines and studies the function of single-enzyme with nanopores, i.e. nanopore enzymology. His research is at the interface of chemistry, biology and physics and is centred on the understanding and manipulation of protein function and structure. Giovanni’s group has applied new methodologies in the nanopore field, allowing the isolation of nanopores with different size, properties and functions. Giovanni’s group main research interests lies in the development a new class of low-cost and portable biosensor for the detection of biomarkers linked to disease; the use of nanopores as nanoreactors to investigate the activity of unlabeled enzyme at the single-molecule level; and, engineering nanopores for single-molecule protein sequencing;

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Giovanni Maglia and Graham Knowles.


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.